Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander E Perl

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Blood Advances|October 6, 2025
FLT3-ITD measurable residual disease from the QuANTUM-First trialMark J Levis, Harry P Erba, Pau Montesinos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemiaAlexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
The Lancet. Oncology|June 9, 2019
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trialJorge E Cortes, Samer Khaled, Giovanni Martinelli, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Lancet (London, England)|April 28, 2023
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialHarry P Erba, Pau Montesinos, Hee-Je Kim, et al.
Blood|May 4, 2013
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemiaCourtney D DiNardo, Kathleen J Propert, Alison W Loren, et al.
Transplantation and Cellular Therapy|November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid MalignanciesMatthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
The Journal of Clinical Investigation|November 13, 2012
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growthLori S Hart, John T Cunningham, Tatini Datta, et al.
Cancer Discovery|May 16, 2019
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid LeukemiaChristine M McMahon, Timothy Ferng, Jonathan Canaani, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Blood Advances|October 6, 2025
FLT3-ITD measurable residual disease from the QuANTUM-First trialMark J Levis, Harry P Erba, Pau Montesinos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemiaAlexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
The Lancet. Oncology|June 9, 2019
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trialJorge E Cortes, Samer Khaled, Giovanni Martinelli, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Lancet (London, England)|April 28, 2023
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialHarry P Erba, Pau Montesinos, Hee-Je Kim, et al.
Blood|May 4, 2013
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemiaCourtney D DiNardo, Kathleen J Propert, Alison W Loren, et al.
Transplantation and Cellular Therapy|November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid MalignanciesMatthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
The Journal of Clinical Investigation|November 13, 2012
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growthLori S Hart, John T Cunningham, Tatini Datta, et al.
Cancer Discovery|May 16, 2019
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid LeukemiaChristine M McMahon, Timothy Ferng, Jonathan Canaani, et al.
Pageof 9